North American Over the Counter Drugs Market 2018-2023 Forecast to Reach $55.6 Billion with Sanofi, GlaxoSmithKline, Pfizer and Bayer Dominating -

The North America over-the-counter market was valued at US$43.341 billion in 2017 and is projected to expand at a CAGR of 4.24% over the forecast period to reach US$55.618 billion by 2023.

Over the counter drugs are those drugs that are available to the consumers without the prescription. The high frequency of occurrences for many of the symptoms for which the over the counter medicines are required is driving the growth of the market. Moreover, the ability to provide convenience value along with growing disposable income is further supplementing the growth of the market.

This research study examines the current market trends related to the demand, supply, and sales, in addition to the recent developments. Major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented in key countries. Further, the overall regulatory framework of the market has been exhaustively covered to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Major industry players profiled as part of the report are Sanofi, GlaxoSmithKline PLC, Pfizer Inc., and Bayer AG others.

Key Topics Covered

1. Introduction

2. Research Methodology

3. Executive Summary

4. Market Dynamics

5. North America Over the Drugs Market by Products

6. North America Over the Counter Drugs Market by Mode of Administration

7. North America Over the Counter Drugs Market by Countries

8. Competitive Intelligence

9. Company Profiles

  • Sanofi
  • Johnson & Johnson Inc.
  • Novartis AG
  • Pfizer Inc.
  • GlaxoSmithKline PLC
  • PGT Healthcare
  • Takeda Pharmaceutical Company

For more information about this report visit


Back to news